These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8615021)

  • 21. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
    Chiou SH; Freed EO; Panganiban AT; Kenealy WR
    AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1611-8. PubMed ID: 1457207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents.
    Rausch DM; Hwang KM; Padgett M; Voltz AH; Rivas A; Engleman E; Gaston I; McGrath M; Fraser B; Kalyanaraman VS
    Ann N Y Acad Sci; 1990; 616():125-48. PubMed ID: 2078014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes.
    Ono M; Wada Y; Wu Y; Nemori R; Jinbo Y; Wang H; Lo KM; Yamaguchi N; Brunkhorst B; Otomo H; Wesolowski J; Way JC; Itoh I; Gillies S; Chen LB
    Nat Biotechnol; 1997 Apr; 15(4):343-8. PubMed ID: 9094135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
    Wild CT; Shugars DC; Greenwell TK; McDanal CB; Matthews TJ
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9770-4. PubMed ID: 7937889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPC3, a nontoxic peptide inhibitor of HIV infection.
    Sabatier JM; Baghdiguian S; Yahi N; Rochat H; Van Rietschoten J; Fantini J
    In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):415-8. PubMed ID: 8589880
    [No Abstract]   [Full Text] [Related]  

  • 27. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320).
    Buckheit RW; Roberson JL; Lackman-Smith C; Wyatt JR; Vickers TA; Ecker DJ
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1497-506. PubMed ID: 7888204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of L- and D-REKR amino acid-containing peptides on HIV and SIV envelope glycoprotein precursor maturation and HIV and SIV replication.
    Bahbouhi B; Chazal N; Seidah NG; Chiva C; Kogan M; Albericio F; Giralt E; Bahraoui E
    Biochem J; 2002 Sep; 366(Pt 3):863-72. PubMed ID: 12071862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
    Lai W; Huang L; Ho P; Li Z; Montefiori D; Chen CH
    Antimicrob Agents Chemother; 2008 Jan; 52(1):128-36. PubMed ID: 17954689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Random copolymers containing specific ratios of negatively charged and aromatic amino acids bind V3 disulfide loop and neutralize diverse HIV type 1 isolates.
    Javaherian K; McDanal C
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1163-8. PubMed ID: 8573371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.
    Savarino A; Bensi T; Chiocchetti A; Bottarel F; Mesturini R; Ferrero E; Calosso L; Deaglio S; Ortolan E; Buttò S; Cafaro A; Katada T; Ensoli B; Malavasi F; Dianzani U
    FASEB J; 2003 Mar; 17(3):461-3. PubMed ID: 12551845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
    Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
    Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
    Pritsker M; Jones P; Blumenthal R; Shai Y
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7287-92. PubMed ID: 9636141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
    Wild C; Oas T; McDanal C; Bolognesi D; Matthews T
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
    Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
    ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR; Strick N; Debnath AK
    J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Düzgünes N
    Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
    Este JA; Schols D; De Vreese K; Van Laethem K; Vandamme AM; Desmyter J; De Clercq E
    Mol Pharmacol; 1997 Jul; 52(1):98-104. PubMed ID: 9224818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
    Jin BS; Ryu JR; Ahn K; Yu YG
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.